Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089441 | 0.85 | EPHX2 (0.58) | EPHX2HPGD | |
| SCHEMBL3939273 | 0.82 | EPHX2 (1.00) | EPHX2HIF1AEPAS1HPGD | |
| SCHEMBL4089403 | 0.81 | EPHX2 (0.73) | EPHX2HPGD | |
| SCHEMBL3347907 | 0.76 | EPHX2 (1.00) | EPHX2HPGD | |
| SCHEMBL3939192 | 0.76 | EPHX2 (1.00) | EPHX2HPGD | |
| SCHEMBL3947089 | 0.76 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL3994030 | 0.76 | EPHX2 (0.70) | EPHX2 | |
| SCHEMBL28363944 | 0.75 | SMN1; SMN2 (0.70) | EPHX2HIF1AEPAS1HPGD | |
| SCHEMBL4089480 | 0.75 | EPHX2 (0.75) | EPHX2HPGD | |
| SCHEMBL4093244 | 0.74 | EPHX2 (0.67) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885HIF1A 527/4885EPAS1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.